Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Myriad GeneticsFRA:MYD +1.90%42 12-1 Month Momentum % is -58.93% as of Sep. 15, 2026. GuruFocus rates FRA:MYD with a GF Score™ of 42/100 and a GF Value™ of €9.49 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, Myriad Genetics ranks worse than 91.08% on this metric.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-09-15), Myriad Genetics's 12-1 Month Momentum % is -58.93%.
The industry rank for Myriad Genetics's 12-1 Month Momentum % or its related term are showing as below:
FRA:MYD's 12-1 Month Momentum % is ranked worse than 91.08% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: -9.89
vs FRA:MYD: -58.93
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Myriad Genetics 12-1 Month Momentum % Related Terms
FRA:MYD vs BDSX, XGN, IMDX: 12-1 Month Momentum % Comparison
For the Diagnostics & Research subindustry, Myriad Genetics's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Myriad Genetics 12-1 Month Momentum % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Myriad Genetics's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Myriad Genetics's 12-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a 12-1 Month Momentum % of -58.93% mean?
Myriad Genetics (FRA:MYD) has a 12-1 Month Momentum % of -58.93% as of Sep. 15, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Myriad Genetics and its competitors. According to the industry distribution chart, Myriad Genetics ranks #194 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 91.1%.
Is Myriad Genetics' 12-1 Month Momentum % too high?
Myriad Genetics' current 12-1 Month Momentum % is -58.93%. Based on the distribution chart, Myriad Genetics ranks #194 out of 213 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Myriad Genetics has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Myriad Genetics' 12-1 Month Momentum % compare to BDSX and XGN?
According to the Medical Diagnostics & Research industry distribution chart, Myriad Genetics ranks #194 out of 213 companies for 12-1 Month Momentum %. This places Myriad Genetics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Medical Diagnostics & Research company?
A good 12-1 Month Momentum % depends on the Medical Diagnostics & Research industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Myriad Genetics and its competitors. Myriad Genetics's current 12-1 Month Momentum % is -58.93%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Myriad Genetics stock overvalued right now?
Based on GuruFocus' analysis, Myriad Genetics (FRA:MYD) is currently considered Possible Value Trap. The stock's GF Value™ is €9.49, compared to a current price of €2.90 — trading 69.5% below its estimated fair value. The current 12-1 Month Momentum % is -58.93%. Myriad Genetics' overall GF Score™ is 42/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Myriad Genetics (FRA:MYD), the current 12-1 Month Momentum % is -58.93% as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Myriad Genetics (FRA:MYD) Overvalued in 2026?
Based on GuruFocus' analysis, Myriad Genetics stock appears to be undervalued.
The current stock price of €2.90 is trading 69.5% below its estimated GF Value™ of €9.49.
GuruFocus considers Myriad Genetics to be Possible Value Trap.
Key valuation signals for FRA:MYD:
12-1 Month Momentum %: -58.93%
GF Value™: €9.49 vs. price of €2.90 (69.5% below fair value)
No single metric tells the full story. See the FRA:MYD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
42GF Score
Get the complete analysis for FRA:MYD
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:MYD has been successfully added to your 
